FGF21 Protein (AA 29-209, N-Term)

Catalog No. ABIN2666736

This Recombinant FGF21 protein is expressed in Escherichia coli (E. coli).

Quick Overview for FGF21 Protein (AA 29-209, N-Term) (ABIN2666736)

Target: FGF21 (Fibroblast Growth Factor 21 (FGF21))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 29-209, N-Term

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: The ED50 is 0.05 - 0.4 μg/ml, corresponding to a specific activity 0.25 - 2 x 104 units/mg, as determined by a dose-dependent stimulation of NIH3T3 cell proliferation in the presence of 4 μg/ml of recombinant mouse β-klotho and 10 μg/ml heparin.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one week, at -20°C for three months, or at -70°C for 6 months.

Target Details

Target: FGF21 (Fibroblast Growth Factor 21 (FGF21))

Alternative Name: FGF-21

Background: FGF-21 is an atypical member of the FGF superfamily and functions as an endocrine hormone. It is mainly secreted by the liver but also by other tissues including adipocytes, pancreas, and skeletal muscle. It can act not only locally but also can travel through the circulatory system and function as an endocrine hormone. FGF-21 signals through a complex formed by classic FGF receptors and the coreceptor β-Klotho. Although it has been shown that FGF-21 can bind all FGFR isotypes, in vitro studies have shown that FGF-21 prefers FGFR1c/β-Klotho complex. Since the expression of β-Klotho is restricted to several tissues including liver, adipose tissues, pancreas, CNS and testes, it is believed that these tissues are the major sites of FGF-21 action. In liver, FGF-21 can induce gluconeogenesis, fatty acid oxidation, triglyceride degradation and ketogenesis. It has also been reported that PGC-1α, a key regulator of mitochondrial energy metabolism, can be induced by FGF-21. In adipose tissue, FGF-21 regulates lipolysis and stimulates glucose uptake independent of insulin. In pancreatic islets, FGF-21 can increase insulin expression. Transgenic mice overexpressing FGF-21 are protected from diet-induced obesity, therefore, FGF-21 has been considered a promising potential therapy for the treatment of obesity-related disorders. FGF-21 can cross the blood-brain barrier and FGF-21 has been shown to regulate peripheral metabolism and circadian behavior by acting on the nervous system.

Molecular Weight: The 187 amino acid recombinant protein has a predicted molecular mass of approximately 20 kDa. The DTT-reduced and non-reduced protein migrate at approximately 20 kDa by SDS-PAGE. The predicted N-terminal amino acid is Met.

Pathways: RTK Signaling